0QAH Aktienübersicht Merck & Co. ist ein weltweit tätiges Gesundheitsunternehmen. Mehr Details
Belohnungen Risikoanalyse Alle Risikoprüfungen anzeigen Community vs My Fair Value Select a narrative for quick price alerts from the community, or create your own.
Merck & Co., Inc. Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Merck Historische Aktienkurse Aktueller Aktienkurs US$82.46 52-Wochen-Hoch US$152.06 52-Wochen-Tief US$75.40 Beta 0.44 1 Monat Veränderung -0.77% 3 Monate Veränderung -8.58% 1 Jahr Veränderung -35.38% 3 Jahre Veränderung -5.96% 5 Jahre Veränderung 6.54% Veränderung seit IPO 133.72%
Aktuelle Nachrichten und Updates
New minor risk - Insider selling May 05
Merck Announces Results from the Phase 3 KEYNOTE-689 Trial Evaluating KEYTRUDA Apr 28
First quarter 2025 earnings released: EPS: US$2.01 (vs US$1.88 in 1Q 2024) Apr 25 Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
Merck & Co., Inc., Annual General Meeting, May 27, 2025 Apr 12
Merck Announces First Presentation of Results from the Phase 3 Zenith Trial Evaluating Winrevair™ Mar 31 Weitere Updates anzeigen
New minor risk - Insider selling May 05
Merck Announces Results from the Phase 3 KEYNOTE-689 Trial Evaluating KEYTRUDA Apr 28
First quarter 2025 earnings released: EPS: US$2.01 (vs US$1.88 in 1Q 2024) Apr 25 Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
Merck & Co., Inc., Annual General Meeting, May 27, 2025 Apr 12
Merck Announces First Presentation of Results from the Phase 3 Zenith Trial Evaluating Winrevair™ Mar 31
Merck & Co., Inc.'s Investigational Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Demonstrates Noninferior Pharmaceuticaletics Compared to Intravenous (IV) KEYTRUDA®? (Pembrolizumab) in Pivotal 3475A-D77 Trial Mar 27
European Commission Approves Merck's Capvaxive®? (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Mar 26
Merck Data At Acc.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease Mar 20
Merck Announces Positive Data from Phase 3 Trials That Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravir/Islatravir Maintained HIV-1 Viral Suppression At Week 48 Mar 13
Upcoming dividend of US$0.81 per share Mar 10
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Feb 25
Merck Receives First European Commission Approval for Two Indications Feb 18 Health Canada Approves Merck's KEYTRUDA® (Pembrolizumab) for the Treatment of Adult Patients with Respirable Non-Small Cell Lung Cancer
Independent Director recently bought US$1.3m worth of stock Feb 09
Merck Announces Phase 3 Waveline-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Feb 06
Full year 2024 earnings released: EPS: US$6.74 (vs US$0.14 in FY 2023) Feb 04
Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2025 Feb 04
Third quarter dividend of US$0.81 announced Feb 03
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults Jan 31 Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Merck Announces Second-Quarter 2025 Dividend, Payable on April 7, 2025 Jan 29
FDA Grants Priority Review to Merck's Application for WELIREG (belzutifan) for the Treatment of Patients with Advanced Pheochromocytoma and Paraganglioma (PPGL) Jan 28
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (Pembrolizumab) Plus LENVIMA (Lenvima) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma Jan 24
Merck’s GARDASIL® Receives Expanded Approval for Males in China Jan 08
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection Dec 19
Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season Dec 18
Merck & Co., Inc. Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab Dec 17
Merck Receives Positive EU CHMP Opinion for WELIREG®? (belzutifan) as Treatment for Adult Patients with Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients with Advanced Renal Cell Carcinoma Dec 14
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer Dec 10
Merck & Co., Inc. Announces First Presentation of Data from the Phase 2 Waveline-007 Trial Evaluating Zilovertamab Vedotin Dec 09
Merck & Co., Inc. Announces Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIOTM (Molnupiravir) for the Treatment of Covid-19 in High-Risk Adults Dec 05
Merck's Sacituzumab Tirumotecan Granted FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC Dec 03
Merck Announces Pivotal Phase 3 Zenith Trial Evaluating Winrevair Met Primary Endpoint At Interim Analysis Nov 26
Third quarter dividend of US$0.81 announced Nov 25
Merck & Co., Inc. Appoints Surendralal L. Karsanbha to its Board of Directors, Effective January 1, 2025 Nov 23
Merck & Co., Inc.'s WELIREG (Belzutifan) Approves in China for the Treatment of Adult Patients with Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors Nov 22
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Met Primary Endpoints Nov 20
Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma Nov 15 Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial
Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement Nov 09
New minor risk - Earnings quality Nov 01
Third quarter 2024 earnings released: EPS: US$1.24 (vs US$1.87 in 3Q 2023) Nov 01
Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC) Oct 28
CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older Oct 26
Merck's KEYTRUDA® (Pembrolizumab) Receives 30th Approval from European Commission with Two New Indications in Gynecologic Cancers Oct 25
Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 Oct 21
Merck Announces the Presentation of Positive Results from the Phase 2B/3 Clinical Trial (Mk-1654-004) Evaluating Clesrovimab Oct 18
Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease Oct 16
Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 10
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma Sep 18
Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab) Sep 16
Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer Aug 02
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer Jun 27
Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab) Jun 05
IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer Mar 12
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 Mar 07
Merck Reportedly in Talks to Buy Harpoon Therapeutics Jan 08 Moderna, Inc. And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
Merck and Moderna Initiates INTerpath-002, A Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with Keytruda® (Pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer Dec 12
Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma Dec 08
Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer Sep 23
Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma Aug 26
Miller Law LLC and Motley Rice LLC Announce a Proposed Settlement in re Zetia (Ezetimibe) Antitrust Litigation Jun 30
Merck & Co., Inc. (NYSE:MRK) completed the acquisition of Prometheus Biosciences, Inc. (NasdaqGS:RXDX) from a group of shareholders. Jun 17 U.S. FDA Approves New Indication for Merck's PREVYMIS®? (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
Merck and Canadian Cancer Trials Group Announces Results from the Phase 3 CCTG IND.227/KeyNOTE-483 Trial Evaluating KEYTRUDA Jun 04
Astrazeneca and MSD's Lynparza (Olaparib) Approves in the US for the Treatment of Metastatic Castration-Resistant Prostate Cancer Jun 01
Merck Declares Quarterly Dividend on Common Stock for the Third Quarter of 2023, Payable on July 10, 2023 May 24 U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk
Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint from Phase 3 Propel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium Feb 17
Merck Announces Phase 3 NRG-GY018 Trial Evaluating Keytrudav Feb 04
Merck & Co., Inc. Provides Earnings Guidance for the Year 2023 Feb 03
Merck Announces the U.S. Food and Drug Administration (FDA) has Approved KEYTRUDA Jan 28 Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
Merck Announces Dividend for the Second-Quarter of 2023 , Payable on April 10, 2023 Jan 25
Teon Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate Tt-816, A Novel Oral Immune Response Modifier, in Combination with Keytruda® (Pembrolizumab) Jan 19 Aktionärsrenditen 0QAH GB Pharmaceuticals GB Markt 7D -1.2% 2.8% 2.1% 1Y -35.4% -8.9% 2.2%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: 0QAH unter dem Niveau der Branche UK Pharmaceuticals , die im vergangenen Jahr eine Rendite von -8.9% erzielte.
Rendite vs. Markt: 0QAH hinter dem Markt UK zurück, der im vergangenen Jahr eine Rendite von 2.2 erzielte.
Preisvolatilität Is 0QAH's price volatile compared to industry and market? 0QAH volatility 0QAH Average Weekly Movement 4.2% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 5.7% 10% most volatile stocks in GB Market 10.8% 10% least volatile stocks in GB Market 3.1%
Stabiler Aktienkurs: 0QAH hatte in den letzten 3 Monaten im Vergleich zum UK -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: 0QAHDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen Merck & Co. ist ein weltweit tätiges Gesundheitsunternehmen. Es ist in zwei Segmenten tätig: Pharmazeutika und Tiergesundheit. Das Unternehmen bietet Pharmazeutika für die menschliche Gesundheit in verschiedenen Bereichen an, darunter Onkologie, Impfstoffe, Akutversorgung im Krankenhaus, Herz-Kreislauf, Virologie, Neurowissenschaften und Diabetes unter den Namen Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, und Janumet.
Mehr anzeigen Merck & Co., Inc.'s Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Merck im Vergleich zum Marktanteil des Unternehmens? 0QAH grundlegende Statistiken Marktanteil US$208.87b Gewinn(TTM ) US$17.43b Umsatz(TTM ) US$63.92b
11.9x Kurs-Gewinn-Verhältnis
3.3x Kurs-Umsatz-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) 0QAH Gewinn- und Verlustrechnung (TTM ) Einnahmen US$63.92b Kosten der Einnahmen US$14.66b Bruttogewinn US$49.27b Sonstige Ausgaben US$31.83b Umsatz US$17.43b
Zuletzt gemeldete Gewinne
Mar 31, 2025
Datum des nächsten Gewinnberichts
Jul 29, 2025
Gewinn per Aktie (EPS) 6.94 Bruttomarge 77.07% Nettogewinnspanne 27.27% Schulden/Eigenkapital-Verhältnis 72.0%
Wie hat sich 0QAH auf lange Sicht entwickelt?
Historische Performance und Vergleiche Dividenden
3.9% Aktuelle Dividendenrendite
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2025/05/05 03:13 Aktienkurs zum Tagesende 2025/05/05 00:00 Gewinne 2025/03/31 Jährliche Einnahmen 2024/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr .
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github .
Analysten-Quellen Merck & Co., Inc. wird von 55 Analysten beobachtet. 24 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung David Toung Argus Research Company Fabrizio Spagna Axia Financial Research Charles Butler Barclays
52 weitere Analysten anzeigen 
